Management of Parkinson Disease: Defining the Role of Ropinirole

Disease Management and Health Outcomes

Volumn 12, Issue 1, 2004, Pages 39-54

  Murdoch, David ^a   Cheer, Susan M ^a   Wagstaff, Antona J ^a  

^a ADIS INTERNATIONAL INC   (United States)

Author keywords

Disease management; Dopamine agonists; Parkinson disease; Review on treatment; Ropinirole

Indexed keywords

AMANTADINE; BENZATROPINE; BROMOCRIPTINE; CABERGOLINE; CATECHOL METHYLTRANSFERASE INHIBITOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; ENTACAPONE; LEVODOPA; PERGOLIDE; PRAMIPEXOLE; ROPINIROLE; SELEGILINE; TOLCAPONE; TRIHEXYPHENIDYL;

BRADYKINESIA; CLINICAL TRIAL; CONFUSION; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DIZZINESS; DRUG TOLERABILITY; DYSKINESIA; HALLUCINATION; HEADACHE; HEART ARRHYTHMIA; HUMAN; HYPOTENSION; INSOMNIA; LOW DRUG DOSE; NAUSEA; NEUROPROTECTION; NIGHTMARE; PARKINSON DISEASE; PATHOPHYSIOLOGY; PSYCHOSIS; QUALITY OF LIFE; REVIEW; RIGIDITY; SIDE EFFECT; SOMNOLENCE; TREMOR; VOMITING;

EID: 1442310968     PISSN: 11738790     EISSN: None     Source Type: Journal    
DOI: 10.2165/00115677-200412010-00004     Document Type: Review

References (92)

1. Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology 2001 Jun: 56 (11 Suppl. 5): 1-88
2. Rubenstein LM, DeLeo A, Chrischilles EA. Economic and health-related quality of life considerations of new therapies in Parkinson's disease. Pharmacoeconomics 2001; 19 (7): 729-52
3. Hauser RA, Zesiewicz TA. Management of early Parkinson's disease. Med Clin North Am 1999 Mar; 83 (2): 393-414
4. Matheson AJ, Spencer CM. Ropinirole: a review of its use in the management of Parkinson's disease. Drugs 2000 Jul; 60 (1): 115-37
5. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson's disease. Arch Neurol 1999 Jan; 56: 33-9
6. Hoehn MM. The natural history of Parkinson's disease in the pre-levodopa and post-levodopa eras. Neurol Clin 1992 May; 10 (2): 331-9
7. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967 May; 17 (5): 427-42
8. Kuhn W, Winkel R, Woitalla D, et al. High prevalence of parkinsonism after occupational exposure to lead-sulfate batteries. Neurology 1998 Jun; 50 (6): 1885-6
9. Choi IS. Parkinsonism after carbon monoxide poisoning. Eur Neurol 2002; 48 (1): 30-3
10. Gorell JM, Rybicki BA, Johnson CC, et al. Occupational metal exposures and the risk of Parkinson's disease. Neuroepidemiology 1999; 18 (6): 303-8
11. Kim Y, Kim JM, Kim JW, et al. Dopamine transporter density is decreased in parkinsonian patients with a history of manganese exposure: what does it mean? Mov Disord 2002; 17 (3): 568-75
12. Gorell JM, Johnson CC, Rybicki BA, et al. The risk of Parkinson's disease with exposure to pesticides, farming, well water, and rural living. Neurology 1998 May; 50 (5): 1346-50
13. Marder K, Logroscino G, Alfaro B, et al. Environmental risk factors for Parkinson's disease in an urban multiethnic community. Neurology 1998 Jan; 50 (1): 279-81
14. Olanow CW. An introduction to the free radical hypothesis in Parkinson's disease. Ann Neurol 1992; 32 Suppl.: S2-9
15. Gorell JM, Rybicki BA, Johnson CC, et al. Smoking and Parkinson's disease: a dose-response relationship. Neurology 1999 Jan 1; 52 (1): 115-9
16. Ross GW, Abbott RD, Petrovitch H, et al. Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA 2000; 283 (20): 2674-9
17. Tanner CM, Ottman R, Goldman SM, et al. Parkinson disease in twins: an etiologic study. JAMA 1999 Jan 27: 281 (4): 341-6
18. Richter G, Sonnenschein A, Grunewald T, et al. Novel mitochondrial DNA mutations in Parkinson's disease. J Neural Transm 2002 May; 109: 721-9
19. Hristova AH, Koller WC. Early Parkinson's disease: what is the best approach to treatment? Drugs Aging 2000 Sep; 17 (3): 165-81
20. Early Parkinson's disease: dopamine agonists have increasingly important role in symptom management. Drug Ther Perspect 2001 Aug 27; 17 (17): 5-10
21. Dodel RC, Berger K, Oertel WH. Health-related quality of life and healthcare utilisation in patients with Parkinson's disease: impact of motor fluctuations and dyskinesias. Pharmacoeconomics 2001; 19 (10): 1013-38
22. Iskedjian M, Einarson TR. Cost analysis of ropinirole versus levodopa in the treatment of Parkinson's disease. Pharmacoeconomics 2003; 21 (2): 115-27
23. Chio A, Magnani C, Schiffer D, et al. Prevalence of Parkinson's disease in Northwestern Italy: comparison of tracer methodology and clinical ascertainment of cases. Mov Disord 1998; 13 (3): 400-5
24. Kuopio AM, Marttila RJ, Helenius H, et al. Changing epidemiology of Parkinson's disease in southwestern Finland. Neurology 1999 Jan 15; 52 (2): 302-8
25. Wermuth L, Joensen P, Bunger N, et al. High prevalence of Parkinson's disease in the Faroe Island. Neurology 1997; 49 (2): 426-32
26. Melcon MO, Anderson DW, Vergara RH, et al. Prevalence of Parkinson's disease in Junin, Buenos Aires Province, Argentina. Mov Disord 1997; 12 (2): 197-205
27. Bower JH, Maraganore DM, McDonnell SK, et al. Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976-1990. Neurology 1999 Apr 12; 52 (6): 1214-20
28. Schrag A, Ben-Shlomo Y, Quinn NP. Cross sectional prevalence survey of idiopathic Parkinson's disease and Parkinsonism in London. BMJ 2000 Jul 1; 321 (7252): 21-2
29. Errea JM, Ara JR, Aibar C, et al. Prevalence of Parkinson's disease in Lower Aragon, Spain. Mov Disord 1999; 14 (4): 596-604
30. Montgomery JR EB. Two advances in the management of Parkinson disease. Cleve Clin J Med 2002 Aug; 69 (8): 639-43
31. Kuzel MD. Ropinirole: a dopamine agonist for the treatment of Parkinson's disease. Am J Health Syst Pharm 1999 Feb 1; 56 (3): 217-24
32. Rubenstein LM, Chrischilles EA, Voelker MD. The impact of Parkinson's disease on health status, health expenditures, and productivity. Estimates from the National Medical Expenditure Survey. Pharmacoeconomics 1997 Oct; 12 (4): 486-98
33. Jenkinson C. Quality-of-life repercussions and costs of Parkinson's disease [in French]. Dis Manage Health Outcomes 2001; 9 (1): 11-9
34. Whetten-Goldstein K, Sloan F, Kulas E, et al. The burden of Parkinson's disease on society, family, and the individual. J Am Geriatr Soc 1997 Jul; 45 (7): 844-9
35. Siderowf AD, Holloway RG, Stern MB. Cost-effectiveness analysis in Parkinson's disease: determining the value of interventions. Mov Disord 2000 May; 15: 439-45
36. LePen C, Wait S, Moutard-Martin F, et al. Cost of illness and disease severity in a cohort of French patients with Parkinson's disease. Pharmacoeconomics 1999 Jul; 16 (1): 59-69
37. Kurlan R, Clark S, Shoulson I, et al. Economic impact of protective therapy for early Parkinson's disease [abstract no. P109]. Ann Neurol 1988 Jul; 24 (1): 153
38. Djaldetti R, Melamed E. Management of response fluctuations: paractical guidelines. Neurology 1998 Aug; 51 (2 Suppl. 2): S36-40
39. Vidailhet M, Bonnet AM, Marconi R, et al. The phenomenology of L-dopa-induced dyskinesias in Parkinson's disease. Mov Disord 1999; 14 Suppl. 1: 13-8
40. Fahn S. The spectrum of levodopa-induced dyskinesias. Ann Neurol 2000; 47 Suppl. 1: S2-S11
41. Koller WC. Levodopa in the treatment of Parkinson's disease. Neurology 2000; 55 (11 Suppl. 4): S2-7; discussion S8-12
42. Koller WC. Treatment of early Parkinson's disease. Neurology 2002; 58 (4 Suppl. 1): S79-86
43. Dooley M, Markham A. Pramipexole: a review of its use in the management of early and advanced Parkinson's disease. Drugs Aging 1998 Jun; 12 (6): 495-514
44. Contin M, Riva R, Albani F, et al. Pharmacokinetic optimisation of dopamine receptor agonist therapy for Parkinson's disease. CNS Drugs 2000 Dec; 14 (6): 439-55
45. Colosimo C, De Michele M. Motor fluctuations in Parkinson's disease: pathophysiology and treatment. Eur J Neurol 1999 Jan; 6 (1): 1-21
46. Le WD, Jankovic J. Are dopamine receptor agonists neuroprotective in Parkinson's disease? Drugs Aging 2001; 18 (6): 389-96
47. Whone AL, Watts RL, Stoessl AJ, et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol 2003 Jul; 54 (1): 93-101
48. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002 Apr 3; 287 (13): 1653-61
49. Schrag A, Keens J, Warner J. Ropinirole for the treatment of tremor in early Parkinson's disease. Eur J Neurol 2002 May; 9 (3): 253-7
50. Arle JE, Alterman RL. Surgical options in Parkinson's disease. Med Clin North Am 1999 Mar; 83 (2): 483-98
51. Hallett M, Litvan I. Evaluation of surgery for Parkinson's disease: a report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. The Task Force on Surgery for Parkinson's Disease. Neurology 1999 Dec 10; 53 (9): 1910-21
52. Lang AE. Surgery for Parkinson disease: a critical evaluation of the state of the art. Arch Neurol 2000 Aug; 57 (8): 1118-25
53. Ropinirole hydrochloride. Mosby's Drug Consult 2003, 2789-94
54. Whone AL, Rakshi JS, Watts DJ, et al. Two trials demonstrating disease-slowing effects of ropinirole, compared with L-dopa, in early Parkinson's disease [abstract no. P242]. Mov Disord 2002; 17 Suppl. 5: S85-6
55. Rascol O, Brooks DJ, Korczyn AD, et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 2000 May 18; 342 (20): 1484-91
56. Korczyn AD, Brunt ER, Larsen JP, et al. A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson's disease. The 053 Study Group [erratum published in Neurology 1999 Sep 22; 53: 1162]. Neurology 1999 Jul 22; 53 (2): 364-70
57. Sethi KD, O'Brien CF, Hammerstad JP, et al. Ropinirole for the treatment of early Parkinson disease: a 12-month experience. Ropinirole Study Group. Arch Neurol 1998 Sep; 55 (9): 1211-6
58. 2 agonist, as sole dopaminergic therapy in Parkinson's disease. Clin Neuropharmacol 1998; 21 (2): 101-7
59. Adler CH, Sethi KD, Hauser RA, et al. Ropinirole for the treatment of early Parkinson's disease. The Ropinirole Study Group. Neurology 1997 Aug; 49 (2): 393-9
60. Rascol O, Lees AJ, Senard JM, et al. Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson's disease. Clin Neuropharmacol 1996 Jun; 19 (3): 234-45
61. Lieberman A, Olanow CW, Sethi K, et al. A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease. Ropinirole Study Group [erratum in Neurology 1999 Jan 15; 52 (2): 435]. Neurology 1998 Oct; 51 (4): 1057-62
62. Brunt ER, Brooks DJ, Korczyn AD, et al. A six-month multicentre, double-blind, bromocriptine-controlled study of the safety and efficacy of ropinirole in the treatment of patients with Parkinson's disease not optimally controlled by L-dopa. J Neural Transm 2002; 109 (4): 489-502
63. Perez-Aharon J, Abbot RJ, Playfer JR, et al. Ropinirole, a placebo-controlled study of efficacy as adjunct therapy in parkinsonian patients not optimally controlled on L-dopa. Neurology 1994 Apr; 44 Suppl. 2: A244
64. Fabbrini G, Barbanti P, Rum A, et al. Combined levodopa test in the evaluation of efficacy of pergolide and ropinirole [abstract]. Mov Disord 1998; 13 Suppl. 2: 50
65. Im JH, Ha JH, Cho IS, et al. Ropinirole as an adjunct to levodopa in the treatment of Parkinson's disease: a 16-week bromocriptine controlled study. J Neurol 2003; 250 (1): 90-6
66. Gimenez-Roldan S, Esteban EM, Mateo D. Switching from bromocriptine to ropinirole in patients with advanced Parkinson's disease: open label pilot responses to three different dose-ratios. Clin Neuropharmacol 2001; 24 (6): 346-51
67. Canesi M, Antonini A, Mariani CB, et al. Overnight switch to ropinirole improves activities of daily living in Parkinson's disease patients. Neurology 2000; 54 (7 Suppl. 3): A280
68. Korczyn AD, Thalamas C, Adler CH. Dosing with ropinirole in a clinical setting. Acta Neurol Scand 2002 Oct; 106 (4): 200-4
69. Clarke CE, Deane KH. Ropinirole for levodopa-induced complications in Parkinson's disease. Cochrane Database Syst Rev 2000; (3): CD001516
70. Brunt ER, Korczyn AD, Lieberman A, et al. The long-term efficacy of ropinirole as an adjunct to L-dopa. Neurology 1999; 52 Suppl. 2: A408-9
71. Clarke CE, Deane KH. Ropinirole versus bromocriptine for levodopa-induced complications in Parkinson's disease. Cochrane Database Syst Rev 2000; (3): CD001517
72. Weiner WJ, Minagar A, Shulman LM. Ropinirole after pramipexole failure in advanced Parkinson's disease [abstract no. W236]. Ann Neurol 1998 Sep; 44 (3): 502
73. Inzelberg R, Carasso RL, Schechtman E, et al. A comparison of dopamine agonists and catechol-O-methyltransferase inhibitors in Parkinson's disease. Clin Neuropharmacol 2000; 23 (5): 262-6
74. Schrag AE, Brooks DJ, Brunt E, et al. The safety of ropinirole, a selective nonergoline dopamine agonist, in patients with Parkinson's disease. Clin Neuropharmacol 1998; 21 (3): 169-75
75. Korczyn AD, Keens J, Oldham M, et al. The safety and efficacy of ropinirole as early therapy in elderly patients with Parkinson's disease. Neurology 2000 Apr 11; 54 (7 Suppl. 3): A90
76. Fuell D, Gardiner D, Krieder MS. The effect of concomitant selegiline on Parkinson's disease patients treated with ropinirole. Neurology 1998 Apr; 50 (4 Suppl. 4): A279
77. Stocchi F, Destee A. Co-administration of ropinirole and domperidone during rapid dose escalation of the dopamine agonist. Parkinsonism Relat Disord 1998; 4 (4): 183-8
78. SmithKline Beecham Pharmaceuticals. Requip brand of ropinirole hydrochloride tablets. Prescribing information. 2001
79. Chaudhuri KR, Pal S, Brefel-Courbon C. 'Sleep attacks' or 'unintended sleep episodes' occur with dopamine agonists: is this a class effect? Drug Saf 2002; 25 (7): 473-83
80. Larsen JP, Tandberg E. Sleep disorders in patients with Parkinson's disease: epidemiology and management. CNS Drugs 2001; 15 (4): 267-75
81. Clarke CE, Vieregge P, Ziegler M, et al. The impact of L-Dopa-induced dyskinesias on patients' quality of life in Parkinson's disease: a prospective European study [abstract no. P06.109]. Neurology 2002; 58 (7 Suppl. 3): A469
82. Pechevis MR, Clarke CE, Vieregge M, et al. The impact of L-dopa-induced dyskinesia on direct health care and non-health care costs associated with patients with Parkinson's disease: a prospective European study [abstract no. P340]. Mov Disord 2002; 17 Suppl. 5: S115
83. Shimbo T, Hira K, Takemura M, et al. Cost-effectiveness analysis of dopamine agonists in the treatment of Parkinson's disease in Japan. Pharmacoeconomics 2001; 19 (8): 875-86
84. Hoerger TJ, Bala MV, Rowland C, et al. Cost effectiveness of pramipexole in Parkinson's disease in the US. Pharmacoeconomics 1998 Nov; 14 (5): 541-57
85. Bhatia K, Brooks DJ, Burn DJ, et al. Guidelines for the management of Parkinson's disease. Hosp Med 1998 Jun; 59 (6): 469-80
86. Olanow CW, Schapira AHV, Roth T, et al. Falling asleep at the wheel: motor vehicle mishaps in people taking pramipexole and ropinirole [letter]. Neurology 2000 Jan 11; 54 (1): 274-7
87. American Sleep Disorders Association. International classificaction of sleep disorders revised: diagnostic and coding manual. Rochester (MN): American Sleep Disorders Association, 1997
88. Hauser RA, Gauger L, McDowell Anderson W, et al. Pramipexole-induced somnolence and episodes of daytime sleep. Mov Dis 2000; 15 (4): 658-63
89. Ebersbach G, Nordon J, Tracik F. Sleep attacks in Parkinson's disease: polysomnographic recordings. Mov Disord 2000; 15 Suppl. 3: 89
90. Hobson DE, Lang AE, Martin WR, et al. Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement. Disorders Group. JAMA 2002; 287 (4): 455-63
91. Clarke CE, Guttman M. Dopamine agonist monotherapy in Parkinson's disease. Lancet 2002 Nov 30; 360: 1767-9
92. Morrish P. Is it time to abandon functional imaging in the study of neuroprotection? Mov Disord 2002 Mar; 17 (2): 229-32